Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP475055.RAjCiYOxfZEYB39qjVrJpmPOtH8ZbYSOl8XrNA3ostx2s130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP475055.RAjCiYOxfZEYB39qjVrJpmPOtH8ZbYSOl8XrNA3ostx2s130_assertion type Assertion NP475055.RAjCiYOxfZEYB39qjVrJpmPOtH8ZbYSOl8XrNA3ostx2s130_head.
- NP475055.RAjCiYOxfZEYB39qjVrJpmPOtH8ZbYSOl8XrNA3ostx2s130_assertion description "[In clinical samples, EphA5 methylation was detected in 64.1% (75/117) of breast tumors and 28.2% (33/117) of paired normal tissues (P < .001), which was associated with higher tumor grade (P = .024), lymph node metastasis (P = .004), and progesterone receptor-negative status (P = .008).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP475055.RAjCiYOxfZEYB39qjVrJpmPOtH8ZbYSOl8XrNA3ostx2s130_provenance.
- NP475055.RAjCiYOxfZEYB39qjVrJpmPOtH8ZbYSOl8XrNA3ostx2s130_assertion evidence source_evidence_literature NP475055.RAjCiYOxfZEYB39qjVrJpmPOtH8ZbYSOl8XrNA3ostx2s130_provenance.
- NP475055.RAjCiYOxfZEYB39qjVrJpmPOtH8ZbYSOl8XrNA3ostx2s130_assertion SIO_000772 19733895 NP475055.RAjCiYOxfZEYB39qjVrJpmPOtH8ZbYSOl8XrNA3ostx2s130_provenance.
- NP475055.RAjCiYOxfZEYB39qjVrJpmPOtH8ZbYSOl8XrNA3ostx2s130_assertion wasDerivedFrom befree-20140225 NP475055.RAjCiYOxfZEYB39qjVrJpmPOtH8ZbYSOl8XrNA3ostx2s130_provenance.
- NP475055.RAjCiYOxfZEYB39qjVrJpmPOtH8ZbYSOl8XrNA3ostx2s130_assertion wasGeneratedBy ECO_0000203 NP475055.RAjCiYOxfZEYB39qjVrJpmPOtH8ZbYSOl8XrNA3ostx2s130_provenance.